Press Releases

Gilead Announces Posting of FDA Briefing Documents for August 6 Advisory Committee Review of Adefovir Dipivoxil for Chronic Hepatitis B

Adefovir dipivoxil is an investigational oral antiviral agent for the treatment of chronic hepatitis B that was granted a six-month priority review by the FDA. Adefovir dipivoxil works by blocking hepatitis B virus (HBV) DNA polymerase, an enzyme crucial to the replication of HBV in the body. Gilead also has filed applications for marketing approval of adefovir dipivoxil in the European Union and Canada.

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has five marketed products and focuses its research and clinical programs on anti-infectives, including antivirals, antifungals and antibacterials. Headquartered in Foster City, Calif., Gilead has operations in the United States, Europe and Australia.

For more information on Gilead Sciences, please visit the company's Web site at or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACT:          Gilead Sciences, Inc.
                  Susan Hubbard, 650/522-5715 (Investors)
                  Erin Edgley, 650/522-5635 (Media)

Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire.  All rights reserved.